文献速递神经肿瘤

NEO100经calpain-1/RhoA通路抑制胶质瘤干细胞迁移

Inhibition of motility by NEO100 through the calpain-1/RhoA pathway.
PubMed 文献 · J Neurosurg · 2019-08-16

本文研究高纯度紫苏醇制剂NEO100对患者来源胶质瘤干细胞(GSC)的作用。体外实验中NEO100对多种GSC亚型有细胞毒性并诱导内质网应激与凋亡,亚细胞毒性浓度下可阻断迁移和侵袭;颅内荷瘤小鼠经鼻给予NEO100后肿瘤进展减少、总生存提高32%。

要点

  • NEO100在近似IC50剂量下对多种GSC亚型具细胞毒性并诱导凋亡。
  • 微摩尔级亚细胞毒性剂量下NEO100阻断GSC迁移与侵袭。
  • 机制涉及calpain-1下降、RhoA激活增强及Src等激酶活化受抑。

核心结论

  • NEO100可能通过靶向GSC用于GBM治疗,可作为单药或在替莫唑胺休息期作为辅助治疗。

研究设计与样本

  • 患者来源GSC群体体外实验,采用western blot、MTT、胞质钙标记、HPLC及迁移侵袭实验。
  • Athymic小鼠颅内植入GSC的体内实验,评估NEO100对肿瘤进展与总生存的影响。

主要发现

  • NEO100对DNA修复机制不同的各GSC亚型均有细胞毒性。
  • 在近似IC50剂量下诱导ER应激并激活凋亡通路。
  • 亚细胞毒性微摩尔剂量下阻断GSC迁移和侵袭。
  • 伴随calpain-1表达下降与RhoA激活增加,GSC收缩性增强。
  • NEO100阻断Src、p42/44 MAPK、Akt和Stat3的激活。

关键数值与推荐

  • 小鼠颅内GSC肿瘤经鼻给予NEO100后肿瘤进展减少,总生存提高32%。
  • 免疫染色显示NEO100在体内诱导凋亡并减少GSC侵袭。

临床怎么用

  • NEO100有望作为GBM靶向GSC的治疗候选,可单用或在替莫唑胺休息期联合使用。

局限性

  • 研究以患者来源GSC体外实验与小鼠颅内植入模型为主,尚缺乏临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glioblastoma (GBM) is the most aggressive type of brain tumor with a high rate of tumor recurrence, and it often develops resistance over time to current standard of care chemotherapy. Its highly invasive nature plays an essential role in tumor progression and recurrence. Glioma stem cells (GSCs) are a subpopulation of glioma cells highly resistant to treatments and are considered responsible for tumor recurrence. METHODS: Patient-derived populations of GSCs were analyzed by western blot, MTT, and cytoplasmic calcium labeling to determine the cytotoxicity of NEO100. High-performance liquid chromatography was used to evaluate the levels of NEO100 in the cell culture supernatants. The effects of the compound on GSC motility were studied using Boyden chamber migration, 3D spheroid migration and invasion assays, and an mRNA expression PCR array. A RhoA activation assay, western blot, and immunofluorescence techniques were employed to confirm the signaling pathways involved. Intracranial implantation of GSCs in athymic mice was used to evaluate the effects of NEO100 in vivo on tumor progression and overall survival. RESULTS: Here, the authors show how NEO100, a highly purified good manufacturing practices-quality form of perillyl alcohol, is cytotoxic for different subtypes of GSCs, regardless of the mechanisms of DNA repair present. At doses similar to the IC50 (half maximal inhibitory concentration) values, NEO100 induces ER stress and activates apoptotic pathways in all GSC populations tested. At subcytotoxic doses in the micromolar range, NEO100 blocks migration and invasion of GSCs. These results correlate with a decrease in calpain-1 expression and an increase in RhoA activation, leading to enhanced contractility of the GSCs. In addition, NEO100 blocks the activation of the kinases Src, p42/44 MAPK, Akt, and Stat3, all related to cell proliferation and migration. Intranasal administration of NEO100 in mice with GSC-derived intracranial tumors led to a decrease in tumor progression and a 32% increase in overall survival. Immunostaining studies showed that NEO100 induces apoptosis and reduces GSC invasion in vivo. CONCLUSIONS: NEO100 could have significant value targeting GSCs and could be used for GBM therapy as either monotherapy or a coadjuvant therapy during temozolomide rest cycles.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Marín-Ramos NI, Pérez-Hernández M, Tam A, et al. Inhibition of motility by NEO100 through the calpain-1/RhoA pathway. J Neurosurg. 2019. PMID: 31419797. doi:10.3171/2019.5.JNS19798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。